- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03239015
Efficacy and Safety of Precision Therapy in Refractory Tumor
February 16, 2022 updated by: Baodong Qin
Efficacy and Safety of Precision Therapy in Refractory Tumor (Long March Pathway)
This study is intended to evaluate efficacy and safety of targeted precision therapy in patients with refractory tumor, including rare tumor without standard recommended treatment and common tumor after multiple line of therapy.
Study Overview
Status
Recruiting
Conditions
Detailed Description
The individuals recruited in the present study are with solid tumor, mainly including two parts: first, rare tumor without standard recommended treatment such as atypical fibrous histiocytoma; second, common tumor after multiple line of therapy such as lung cancer, gastric cancer, colorectal cancer, etc.
All patients have no any standard therapy based on NCCN guideline when recruiting.
Next-generation sequence was used to detect druggable molecular event including gene mutation, gene fusion, amplification, etc.
Then patients with molecular events were treated with corresponding targeted drug and followed-up, and not limited tumor type.
PD-1/L1 inhibior plus anti-angiogenic agent was used in patients without durgguable targets.
The efficacy and safety of these regimens were evaluated.
Study Type
Interventional
Enrollment (Anticipated)
300
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiao-dong Jiao, MD.PHD
- Phone Number: +86-13817797639
- Email: pulava@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200003
- Recruiting
- Shanghai Changzheng Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Malignant solid tumors diagnosed histologically;
- Common solid tumor patients have no any standard choice after multiple line of therapy; Rare solid tumor did not have any standard recommended treatment;
- Expected survival ≥ 1 month;
- ECOG / PS score: 0-2, and the main organ function to meet the following criteria: HB ≥ 90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL <1.5 times the upper limit of normal (ULN); Liver ALT and AST <2.5 × ULN and if liver metastases, ALT and AST <5 × ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min
Exclusion Criteria:
- Patient still has standard treatment therapy based on NCCN guidance;
- Patient can not comply with research program requirements or follow-up;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Targeted Drug Therapy Group
All recruited patients with druggable molecular event will be treated with corresponding targeted drug including Gefitinib/Erlotinib/Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib/Dabrafenib, and Palbociclib.
If no durggable target, PD-1/L1 inhibitor plus anti-angiogenic agent was used.
|
Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.
Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.
Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.
Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.
Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.
Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.
PD-1/L1 inhibitor plus anti-angiogenic agent is a regimen used for refractory tumor without druggable target
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate
Time Frame: Evaluation of tumor burden based on RECIST criteria through study completion, an average of 2 months
|
Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission
|
Evaluation of tumor burden based on RECIST criteria through study completion, an average of 2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progress Free Survival
Time Frame: Evaluation of tumor burden based on RECIST criteria until first documented progress through study completion, an average of 2 months
|
Time from treatment beginning until disease progression
|
Evaluation of tumor burden based on RECIST criteria until first documented progress through study completion, an average of 2 months
|
Overall Survival
Time Frame: From date of treatment beginning until the date of death from any cause, through study completion, an average of 1 months
|
Time from treatment beginning until death from any cause
|
From date of treatment beginning until the date of death from any cause, through study completion, an average of 1 months
|
Adverse Effect
Time Frame: Through study completion, an average of 1 months
|
Incidence of Treatment-related adverse Events
|
Through study completion, an average of 1 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yuan-Sheng Zang, MD.PHD, Shanghai Changzheng Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2017
Primary Completion (Anticipated)
June 30, 2023
Study Completion (Anticipated)
December 31, 2023
Study Registration Dates
First Submitted
July 28, 2017
First Submitted That Met QC Criteria
August 1, 2017
First Posted (Actual)
August 3, 2017
Study Record Updates
Last Update Posted (Actual)
March 4, 2022
Last Update Submitted That Met QC Criteria
February 16, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Poly(ADP-ribose) Polymerase Inhibitors
- Trastuzumab
- Olaparib
- Palbociclib
- Gefitinib
- Everolimus
- Dabrafenib
- Afatinib
- Vemurafenib
- Angiogenesis Inhibitors
Other Study ID Numbers
- Long March Pathway
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Tumor
-
National Health Research Institutes, TaiwanNational Cheng-Kung University HospitalRecruiting
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyRecruitingSolid Tumor, Adult | Refractory TumorUnited States
-
Sidnei EpelmanUnknown
-
National University Hospital, SingaporeOtsuka Pharmaceutical Co., Ltd.Unknown
-
Second Affiliated Hospital of Soochow UniversitySciClone PharmaceuticalsRecruitingAdvanced Solid Tumor | Refractory TumorChina
-
Sorrento Therapeutics, Inc.RecruitingSolid Tumor | Refractory Tumor | Relapsed Solid NeoplasmUnited States
-
The First Affiliated Hospital of Xiamen UniversityRecruitingRefractory Solid TumorChina
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Samsung Medical CenterMinistry of Health, Republic of KoreaNot yet recruitingRelapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
Clinical Trials on Gefitinib
-
Sun Yat-sen UniversityUnknown
-
Qilu Pharmaceutical Co., Ltd.UnknownNon-small-cell Lung CancerChina
-
Sun Yat-sen UniversityWu Jieping Medical FoundationCompletedNon-small Cell Lung CancerChina
-
Jiangsu Famous Medical Technology Co., Ltd.UnknownNon-small Cell Lung Cancer
-
AstraZenecaCompletedNeoplasms, Squamous CellUnited States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
-
Anhui Medical UniversityUnknownSelf Efficacy | Drug ToxicityChina
-
NCIC Clinical Trials GroupCompletedProstate CancerCanada
-
University of Maryland, BaltimoreNational Cancer Institute (NCI); University of Maryland Greenebaum Cancer CenterCompleted
-
Samsung Medical CenterUnknownNon-small Cell Lung CancerKorea, Republic of
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Cancer | Primary Peritoneal Cavity CancerUnited States, Canada, United Kingdom, Australia